|
Cytos hits the self-destruct button as PhIIb asthma study bombs
FierceBiotech The Swiss biotech said that its asthma drug CYT003 flunked its primary as well as secondary endpoints in the critically important study, making it all but impossible to raise more funds for the company. As a result, CEO Christian Itin has hit the self … Cytos Begins Layoff Process, Eyes Liquidation After Phase IIb Failure Cytos considering options to wind down company |
View full post on asthma – Google News